Published in Eur J Endocrinol on May 01, 2008
Pituitary somatostatin receptor signaling. Trends Endocrinol Metab (2010) 1.03
PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms. Theranostics (2014) 0.95
Prolactinomas, Cushing's disease and acromegaly: debating the role of medical therapy for secretory pituitary adenomas. BMC Endocr Disord (2010) 0.88
PET and PET/CT with 68gallium-labeled somatostatin analogues in Non GEP-NETs Tumors. ScientificWorldJournal (2014) 0.81
Somatostatin receptor biology in neuroendocrine and pituitary tumours: part 2--clinical implications. J Cell Mol Med (2010) 0.77
Peptide receptor targeting in cancer: the somatostatin paradigm. Int J Pept (2013) 0.77
The pituitary TGFβ1 system as a novel target for the treatment of resistant prolactinomas. J Endocrinol (2015) 0.76
BIM-23A760 influences key functional endpoints in pituitary adenomas and normal pituitaries: molecular mechanisms underlying the differential response in adenomas. Sci Rep (2017) 0.75
Gigantism and acromegaly due to Xq26 microduplications and GPR101 mutation. N Engl J Med (2014) 4.00
Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol (2007) 3.23
Chronic treatment with a melanocortin-4 receptor agonist causes weight loss, reduces insulin resistance, and improves cardiovascular function in diet-induced obese rhesus macaques. Diabetes (2012) 1.91
Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab (2002) 1.74
High prevalence of AIP gene mutations following focused screening in young patients with sporadic pituitary macroadenomas. Eur J Endocrinol (2011) 1.69
Phase II study of temozolomide without radiotherapy in newly diagnosed glioblastoma multiforme in an elderly populations. Cancer (2004) 1.58
18F-FDG avidity of pheochromocytomas and paragangliomas: a new molecular imaging signature? J Nucl Med (2009) 1.57
Regulation of prolactin, GH, and Pit-1 gene expression in anterior pituitary by Pitx2: An approach using Pitx2 mutants. Endocrinology (2002) 1.53
Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab (2007) 1.53
Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience. J Clin Endocrinol Metab (2010) 1.46
Identification of adropin as a secreted factor linking dietary macronutrient intake with energy homeostasis and lipid metabolism. Cell Metab (2008) 1.45
Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis. Acta Neuropathol (2010) 1.36
Congenital isolated adrenocorticotropin deficiency: an underestimated cause of neonatal death, explained by TPIT gene mutations. J Clin Endocrinol Metab (2004) 1.29
Ghrelin treatment causes increased food intake and retention of lean body mass in a rat model of cancer cachexia. Endocrinology (2007) 1.25
Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study. J Clin Endocrinol Metab (2010) 1.24
Stereoelectroencephalography in presurgical assessment of MRI-negative epilepsy. Brain (2007) 1.24
Ghrelin treatment of chronic kidney disease: improvements in lean body mass and cytokine profile. Endocrinology (2007) 1.23
Adropin deficiency is associated with increased adiposity and insulin resistance. Obesity (Silver Spring) (2012) 1.19
PROKR2 variants in multiple hypopituitarism with pituitary stalk interruption. J Clin Endocrinol Metab (2012) 1.19
Percutaneous kyphoplasty and pedicle screw fixation for the management of thoraco-lumbar burst fractures. Eur Spine J (2010) 1.17
Analysis of the therapeutic functions of novel melanocortin receptor agonists in MC3R- and MC4R-deficient C57BL/6J mice. Peptides (2009) 1.16
A new prognostic clinicopathological classification of pituitary adenomas: a multicentric case-control study of 410 patients with 8 years post-operative follow-up. Acta Neuropathol (2013) 1.15
Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. J Clin Endocrinol Metab (2009) 1.14
Metagenomic analysis of brain abscesses identifies specific bacterial associations. Clin Infect Dis (2011) 1.11
Functional characterization of nonmetastatic paraganglioma and pheochromocytoma by (18) F-FDOPA PET: focus on missed lesions. Clin Endocrinol (Oxf) (2013) 1.08
Pituitary carcinomas and aggressive pituitary tumours: merits and pitfalls of temozolomide treatment. Clin Endocrinol (Oxf) (2012) 1.08
A genome-wide approach reveals novel imprinted genes expressed in the human placenta. Epigenetics (2012) 1.08
Taspoglutide, an analog of human glucagon-like Peptide-1 with enhanced stability and in vivo potency. Endocrinology (2010) 1.04
Expression of aryl hydrocarbon receptor (AHR) and AHR-interacting protein in pituitary adenomas: pathological and clinical implications. Endocr Relat Cancer (2009) 1.03
Genetic screening of combined pituitary hormone deficiency: experience in 195 patients. J Clin Endocrinol Metab (2006) 1.02
Functional outcome after gamma knife surgery or microsurgery for vestibular schwannomas. J Neurosurg (2002) 1.02
Novel analogs of ghrelin: physiological and clinical implications. Eur J Endocrinol (2004) 1.01
Long-term effects of ghrelin and ghrelin receptor agonists on energy balance in rats. Am J Physiol Endocrinol Metab (2008) 1.01
Solitary fibrous tumors of the central nervous system: clinicopathological and therapeutic considerations of 18 cases. Neurosurgery (2007) 1.00
IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients. J Neurooncol (2011) 0.99
Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab (2007) 0.97
Frequent large germline HRPT2 deletions in a French National cohort of patients with primary hyperparathyroidism. J Clin Endocrinol Metab (2013) 0.96
A new specific succinate-glutamate metabolomic hallmark in SDHx-related paragangliomas. PLoS One (2013) 0.96
Effect of ghrelin and its analogues, BIM-28131 and BIM-28125, on the expression of myostatin in a rat heart failure model. J Cachexia Sarcopenia Muscle (2012) 0.95
Distinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cells. Am J Physiol Endocrinol Metab (2005) 0.95
Genetic analysis in young patients with sporadic pituitary macroadenomas: besides AIP don't forget MEN1 genetic analysis. Eur J Endocrinol (2013) 0.94
Ghrelin, peptide YY and their hypothalamic targets differentially regulate spontaneous physical activity. Physiol Behav (2011) 0.94
Evaluation of fractionated radiotherapy and gamma knife radiosurgery in cavernous sinus meningiomas: treatment strategy. Neurosurgery (2005) 0.94
Combined effects of ghrelin and higher food intake enhance skeletal muscle mitochondrial oxidative capacity and AKT phosphorylation in rats with chronic kidney disease. Kidney Int (2010) 0.93
Detection of genetic hypopituitarism in an adult population of idiopathic pituitary insufficiency patients with growth hormone deficiency. Pituitary (2011) 0.93
Use of a self-expanding stent with balloon angioplasty in the treatment of dural arteriovenous fistulas involving the transverse and/or sigmoid sinus: functional and neuroimaging-based outcome in 10 patients. J Neurosurg (2006) 0.93
The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. Eur J Endocrinol (2006) 0.93
Role of stereotactic radiosurgery in the management of pituitary adenomas. Nat Rev Endocrinol (2010) 0.92
A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs. J Clin Endocrinol Metab (2010) 0.92
Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. J Clin Endocrinol Metab (2005) 0.92
No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure. Int J Cardiol (2008) 0.92
Drug Insight: prolactin-receptor antagonists, a novel approach to treatment of unresolved systemic and local hyperprolactinemia? Nat Clin Pract Endocrinol Metab (2006) 0.91
An uncommon phenotype with familial central hypogonadism caused by a novel PROP1 gene mutant truncated in the transactivation domain. J Clin Endocrinol Metab (2005) 0.91
Cell growth inhibition and functioning of human somatostatin receptor type 2 are modulated by receptor heterodimerization. Mol Endocrinol (2008) 0.90
Dysregulation of 4q35- and muscle-specific genes in fetuses with a short D4Z4 array linked to facio-scapulo-humeral dystrophy. Hum Mol Genet (2013) 0.90
Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas: effects on cell viability, GH, and PRL secretion. J Clin Endocrinol Metab (2003) 0.90
Heterogeneous genetic background of the association of pheochromocytoma/paraganglioma and pituitary adenoma: results from a large patient cohort. J Clin Endocrinol Metab (2014) 0.90
Novel mutations within the POU1F1 gene associated with variable combined pituitary hormone deficiency. J Clin Endocrinol Metab (2005) 0.89
Regulation of growth hormone and prolactin gene expression and secretion by chimeric somatostatin-dopamine molecules. Endocrinology (2007) 0.89
Successful treatment of a giant isolated cerebral mucormycotic (zygomycotic) abscess using endoscopic debridement: case report and therapeutic considerations. Surg Neurol (2007) 0.89
Brain of a white-collar worker. Lancet (2007) 0.89
A novel growth hormone secretagogue-1a receptor antagonist that blocks ghrelin-induced growth hormone secretion but induces increased body weight gain. Neuroendocrinology (2005) 0.89
Selective activation of somatostatin receptor subtypes differentially modulates secretion and viability in human medullary thyroid carcinoma primary cultures: potential clinical perspectives. J Clin Endocrinol Metab (2006) 0.89
Giant fusiform intracranial A2 aneurysm: endovascular and surgical treatment. Case illustration. J Neurosurg (2004) 0.88
Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr Relat Cancer (2008) 0.87
Open kyphoplasty for management of severe osteoporotic spinal fractures. Neurosurgery (2009) 0.87
An unusual presentation of a lumbar synovial cyst: case report. Spine (Phila Pa 1976) (2002) 0.87
Somatostatin-dopamine ligands in the treatment of pituitary adenomas. Rev Endocr Metab Disord (2008) 0.87
Somatostatin receptor sst2 decreases cell viability and hormonal hypersecretion and reverses octreotide resistance of human pituitary adenomas. Cancer Res (2008) 0.87
Inactivation of transcription factor pit-1 to target tumoral somatolactotroph cells. Hum Gene Ther (2012) 0.87
Constitutive somatostatin receptor activity determines tonic pituitary cell response. Mol Endocrinol (2009) 0.86
Somatostatin analogs in vitro effects in a growth hormone-releasing hormone-secreting bronchial carcinoid. J Clin Endocrinol Metab (2005) 0.86
Solitary fibrous tumors and hemangiopericytomas of the meninges: overlapping pathological features and common prognostic factors suggest the same spectrum of tumors. Brain Pathol (2011) 0.86
Discovery of adamantyl ethanone derivatives as potent 11beta-hydroxysteroid dehydrogenase type 1 (11beta-HSD1) inhibitors. ChemMedChem (2010) 0.86